Related Experiment Video
Updated: Jun 22, 2025
11:08
Endothelialized Microfluidics for Studying Microvascular Interactions in Hematologic Diseases
Published on: June 22, 2012
16.0K
Clinical and Economic Implications of Hydroxyurea Intolerance in Polycythemia Vera in Routine Clinical Practice
Martin H Ellis1,2, Tamar Tadmor3,4, Naama Yekutiel5
1Hematology Institute, Meir Medical Center, Kfar Saba 4428164, Israel.
Journal of Clinical Medicine
|June 27, 2024
Summary
Hydroxyurea (HU) intolerance in polycythemia vera (PV) patients is linked to worse clinical outcomes, including higher thrombosis and disease progression rates. HU-intolerant individuals also experienced increased healthcare utilization and costs, emphasizing the need for close monitoring.
Area of Science:
- Hematology
- Oncology
- Clinical Research
Background:
- Polycythemia vera (PV) is a chronic myeloproliferative neoplasm.
- Hydroxyurea (HU) is a common treatment for PV.
- Understanding HU intolerance is crucial for managing PV patients.
Purpose of the Study:
- To investigate the clinical and economic implications of HU intolerance in PV patients in Israel.
- To compare outcomes between HU-intolerant and HU-stable PV patients.
Main Methods:
- Retrospective analysis of a digitalized healthcare database.
- Inclusion of 830 PV patients treated with HU.
- Data collection on demographics, clinical events, healthcare utilization, and costs.
Main Results:
- 38.3% of PV patients were intolerant to HU.
- HU-intolerant patients showed significantly higher rates of venous thrombosis, progression to myelofibrosis, and acute myeloid leukemia (AML).
- HU intolerance was associated with increased phlebotomy, mortality, hospitalizations, mental health events, and healthcare costs (2.65 ratio).
Conclusions:
- HU intolerance in PV patients is associated with poorer clinical outcomes and increased healthcare burden.
- Close monitoring of HU-intolerant PV patients is essential for early detection of complications and disease progression.
- Findings highlight the need for alternative treatment strategies or enhanced supportive care for HU-intolerant individuals.
Related Concept Videos
01:27Disorders of Erythrocytes
928
Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
928
01:24Factors Affecting Erythropoiesis
3.2K
The cardiovascular system regulates the number of erythrocytes in the bloodstream to ensure optimal oxygen transport. It also prevents over-proliferation of these cells, which helps to maintain blood viscosity and flow rate.
Several factors influence the erythrocyte production rate, with tissue oxygen level being among the most critical. Intense exercise or high altitudes can cause tissue hypoxia, which triggers the kidneys to release more erythropoietin (EPO) into the bloodstream.
EPO then...
Several factors influence the erythrocyte production rate, with tissue oxygen level being among the most critical. Intense exercise or high altitudes can cause tissue hypoxia, which triggers the kidneys to release more erythropoietin (EPO) into the bloodstream.
EPO then...
3.2K
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
195
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
195
01:11Renal Failure: Dose Adjustments
79
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
79
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
157
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
157
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
146
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
146